Glenmark Pharmaceuticals today announced that its candidate for treatment of rheumatoid arthritis, inflammation and multiple sclerosis - GRC 4039 - has entered Phase-I trials.
According to a release issued by Glenmark to the BSE today, Phase-I trials are likely to be completed by October 2008, and Phase-II trials could start by January 2009.
Glenn Saldanha, MD & CEO, Glenmark, said: "We are happy to take GRC 4039 forward into Phase-I trials. This is Glenmark’s fourth molecule to enter the clinics from our pipeline of eight NCEs and NBEs, and demonstrates our steady progress in the drug discovery space."
No comments:
Post a Comment